Predominantly hemorrhagic choroidal neovascular lesion from exudative age-related macular degeneration treated with intravitreal ranibizumab therapy

Lesão neovascular predominantemente hemorrágica da degeneração macular relacionada à idade, tratada com ranibizumab intravitrea

Miguel Hage Amaro1; Aaron Brock Holler2

1 Private Practice. Belém (PA) Brazil; 2 Retina Service, University of Iowa, USA. Study carried out at Retina Service, University of Iowa, USA. The authors declare no conflicts of interest

ABSTRACT

The authors relate a predominantly hemorrhagic choroidal neovascular lesion from neovascular. Age-related macular degeneration patient case treated with intravitreal ranibizumab therapy. Monthly ranibizumab (six intravitreal injections) displayed a promising response but this limited report is insufficient to guarantee the indication for all predominantly hemorrhagic choroidal neovascular lesion from neovascular age-related macular degeneration. Further studies will be necessary for complete validation of our results for all predominantly hemorrhagic choroidal neovascular lesions from CNV due to AMD.

Keywords: Macular degeneration/drug therapy; Choroidal neovascularization/drug therapy; Angiogenesis inhibitors/therapeutic use; Antibodies monoclonal; Case reports

RESUMO

Os autores apresentam um caso de paciente com lesão neovascular predominantemente hemorrágica com degeneração macular relacionada à idade, tratada mensalmente com injêções intravitrea com ranibizumab. Discutem sua evolução, que apesar da boa resposta terapêutica, necessita de maiores estudos para confirmação de seus resultados.

Descritores: Degeneração macular /quimioterapia; Neovascularização coroidal/quimioterapia; Inibidores da angiogênese/uso terapêutico; Antibíos monoclonais/uso terapêutico; Relato de casos

1 Private Practice. Belém (PA) Brazil; 2 Retina Service, University of Iowa, USA.

Study carried out at Retina Service, University of Iowa, USA.

The authors declare no conflicts of interest

Received for publication on: 22/7/2011 - Accepted for publication on: 10/6/2012
INTRODUCTION

Predominantly hemorrhagic choroidal neovascular lesions are defined as present when at least 50% of the choroidal neovascular lesion is occupied by blood under the retina (1,2). Predominantly hemorrhagic choroidal neovascular lesions are caused by choroidal neovascularization (CNV) from age-related macular degeneration (AMD) and display a poor prognosis (1,2). At three years of follow-up, the visual outcomes in such cases are reported to be 20/1700 and patients have lost an average of 3.5 lines of Snellen visual acuity (VA) (3,4). The hemorrhage thickness impacts more highly on the final visual acuity than the hemorrhage area, although both display significant visual effects (3). One mechanism of damage is from a subretinal blood barrier effect that prevents photoreceptors from receiving metabolic support from the retinal pigment epithelium and choroids (3,5). The natural course of hemorrhages improve in those not affected by AMD, even in thick hemorrhages, although some experimental models have shown irreversible photoreceptor damage (3).

The visual prognosis improves when the hemorrhage is subretinal, as compared to below the retinal pigment epithelium (RPE), in that when patients with subretinal neovascularization from AMD bleed, the blood spreads beneath the RPE and penetrates the subretinal space (6,7). In other conditions, such as trauma or the presumed ocular histoplasmosis syndrome, the hemorrhage is present almost exclusively in the subretinal space (6,7).

No randomized clinical trials have provided an effective treatment for predominantly hemorrhagic lesions. Submacular surgical trials (SST) found that evacuation of the hemorrhage and associated CNV did not improve or stabilize vision (2,6). The pneumatic displacement of the hemorrhage to avoid possible photoreceptor toxicity and allow visualization of the underlying CNV with subsequent photodynamic therapy treatment or intravitreal agents has also been suggested as a treatment approach. However, no definitive evidence of the precise risks and benefits, as compared to no-treatment or intravitreal anti-vascular endothelial growth factors and drugs including ranibizumab or bevacizumab, have been demonstrated (14-16).

The aim of this report was to assess the results of a predominantly hemorrhagic choroidal neovascular lesion from an exsudative AMD patient treated with intravitreal ranibizumab therapy.

CASE REPORT

A caucasian 78-year old woman who was followed due atrophic geographic AMD (figure 1), right eye color image in both eyes using AREDS formulation displayed a subtle visual loss in her right eye. Through ophthalmological evaluation, the visual acuity was counting fingers in the right eye and 20/200 in the left eye. The anterior segment was unremarkable in both eyes. Fundoscopy examination (figure 2) displayed a predominantly hemorrhagic choroidal neovascular lesion overlying an inferior region of the extense area of a pre-existing geographic AMD. Fluorescein angiography (figure 3 and 4) showed a blockage of fluorescein due to extensive subretinal hemorrhage (predominantly hemorrhagic choroidal neovascular lesions) and dye staining in the residual atrophic area. The stratus OCT presented a central subfield thickness of 649 microns. The patient was treated with monthly intravitreal ranibizumab (0.5 mg/0.05ml), receiving six injections for a total of six months. During this time, Argon green laser photocoagulation around the site of choroidal neovascularization was performed. At the end of the treatment period, the subretinal hemorrhage reabsorbed and subretinal fibrosis developed (figure 5). The visual acuity improved to 20/200 in the eye, with no recurrences in the two years of follow-up.

DISCUSSION

Predominantly hemorrhagic choroidal neovascular lesions due to AMD have not been enrolled in clinical studies (17-20). However, randomized trials using photodynamic therapy with
verteporfin, intravitreal pegaptanib or intravitreal ranibizumab specifically excluded this type of lesion.12,18 Data from MARINA and ANCHOR trials for predominantly hemorrhagic lesions must be performed with caution as it is unclear whether the efficacy of ranibizumab for predominantly hemorrhagic lesions is modulated by the presence of large areas of subretinal blood.19,20

Current research has not indicated whether these drugs can penetrate the target site of the CNV. Although clinical trials have provided no effective treatments for predominantly hemorrhagic lesions, submacular surgery trials (SST) found that treatment for hemorrhages and associated CNV did not improve or stabilize vision.2 A report of a case series reported that the visual acuity of the subjects treated may have been limited through pre-existing retinal damage and subretinal fibrosis due to CNV or the subsequent loss of retinal tissue from the hemorrhage or from the ensuing fibrotic destruction of retinal tissue.18

Intravitreal bevacizumab and ranibizumab therapy for predominantly hemorrhagic CNV has been reported.19,30,36 A case series of bevacizumab in 21 eyes of 19 patients found an improvement in the Snellen VA based on at least a single letter improvement in 48% of the treated eyes, no letter changes in 9%, and a single letter or greater decrease in the Snellen VA in 43% of subjects, 4 months following the first injection19. The median VA did not change from baseline to 4 months and remained at 20/100. When 12 of these eyes were followed for 1 year, only 25% maintained an improvement in vision, 17% displayed no changes and 58% lost at least a single letter of vision. In the ranibizumab series at 12 months, the median visual acuity letter score was 30 (Snellen equivalent: 20/250), with a median change from baseline to last follow-up of +7 letters. Three of 7 subjects (43%) gained 2 or more lines of vision, whilst no subjects lost 2 or more lines. Three month treatment with Sulfur hexafluoride gas, an intravitreal tissue plasminogen activator, and bevacizumab injection in 19 patients with relatively small hemorrhagic lesions, improved the mean VA from 20/133 to 20/74(51). However, this study included only small sized hemorraghes and no extended follow up was performed. In the present case, monthly ranibizumab (six intravitreal injections) displayed a promising response but this limited report is insufficient to guarantee the indication for all predominantly hemorrhagic choroidal neovascular lesions from CNV due to AMD. Further studies will be necessary for complete validation of our results.

Acknowledgement
To professor James Folk, MD, chief of the Vitreoretina service of Iowa University

REFERENCES


